SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 25, 2007
CUBIST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 0-21379 | | 22-3192085 |
(State or Other Jurisdiction | | (Commission | | (IRS Employer |
of Incorporation) | | File Number) | | Identification No.) |
65 Hayden Avenue, Lexington, Massachusetts 02421 |
(Address of Principal Executive Offices)(Zip Code) |
Registrant’s telephone number, including area code: (781) 860-8660
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement.
On October 25, 2007, the registrant, Cubist Pharmaceuticals, Inc. (“Cubist”), and The Realty Associates Fund VI, L.P. (“RA”) entered into a Fourth Amendment to Lease (the “Fourth Amendment”), amending the Lease dated as of January 2004 between Cubist and RA’s predecessor-in-interest, California State Teachers’ Retirement System, as previously amended, pursuant to which Cubist leases space in the building known as 45-55 Hayden Avenue, Lexington, Massachusetts (the “Building”). The Fourth Amendment increases the space that Cubist will lease in the Building from 83,097 rentable square feet to 108,502 rentable square feet and establishes a rental rate per square foot for the new space ranging from $32.25 to $39.25 per square foot over the term of the amended Lease.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | CUBIST PHARMACEUTICALS, INC. |
| | | | | | | |
| | | | | By: | /s/ David W. J. McGirr | |
| | | | | | David W. J. McGirr | |
| | | | | | Senior Vice President and | |
| | | | | | Chief Financial Officer | |
| | | | | | | | |
Dated: October 30, 2007
2
